Prosight Management’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-486,726
| Closed | -$10.5M | – | 55 |
|
|
2022
Q4 | $10.5M | Sell |
486,726
-4,518
| -0.9% | -$95.5K | 5.74% | 5 |
|
|
2022
Q3 | $9.51M | Buy |
491,244
+23,449
| +5% | +$485K | 5.09% | 6 |
|
|
2022
Q2 | $9.29M | Sell |
467,795
-12,205
| -3% | -$322K | 7.32% | 4 |
|
|
2022
Q1 | $14.3M | Sell |
480,000
-34,082
| -7% | -$998K | 9.25% | 3 |
|
|
2021
Q4 | $12M | Buy |
514,082
+69,062
| +16% | +$1.84M | 7.17% | 3 |
|
|
2021
Q3 | $13.9M | Buy |
445,020
+149,940
| +51% | +$4.64M | 7.64% | 2 |
|
|
2021
Q2 | $10.4M | Buy |
295,080
+124,728
| +73% | +$4.06M | 6.49% | 2 |
|
|
2021
Q1 | $6M | Sell |
170,352
-4,439
| -3% | -$164K | 4.92% | 7 |
|
|
2020
Q4 | $6.56M | Buy |
174,791
+52,291
| +43% | +$1.9M | 3.03% | 13 |
|
|
2020
Q3 | $4.09M | Sell |
122,500
-76,300
| -38% | -$2.22M | 1.94% | 20 |
|
|
2020
Q2 | $5.27M | Sell |
198,800
-131,607
| -40% | -$3.1M | 2.26% | 17 |
|
|
2020
Q1 | $5.41M | Buy |
330,407
+83,229
| +34% | +$1.83M | 2.53% | 16 |
|
|
2019
Q4 | $6.28M | Sell |
247,178
-5,322
| -2% | -$106K | 2.76% | 16 |
|
|
2019
Q3 | $5.05M | Sell |
252,500
-827
| -0.3% | -$21.4K | 2.8% | 15 |
|
|
2019
Q2 | $8.17M | Sell |
253,327
-16,509
| -6% | -$552K | 4.12% | 10 |
|
|
2019
Q1 | $8.69M | Sell |
269,836
-310
| -0.1% | -$8.35K | 3.8% | 9 |
|
|
2018
Q4 | $6.63M | Buy |
270,146
+107,241
| +66% | +$2.83M | 3.42% | 10 |
|
|
2018
Q3 | $5.37M | Buy |
+162,905
| New | +$5.33M | 2.99% | 14 |
|
Other funds holding ALBO
Prosight Management's ALBO Position: Q1 2023 in Review
Prosight Management sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 486,726 shares — an estimated $10.5M sold.
Prosight Management first reported a position in ALBO in Q3 2018 and held it in 18 quarters. The position peaked at $14.3M in Q1 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- Prosight Management reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- Prosight Management sold 486,726 Albireo Pharma Inc shares in Q1 2023, an estimated $10.5M.
- Prosight Management first reported a position in Albireo Pharma Inc in Q3 2018 and held it in 18 quarters.
- Prosight Management's Albireo Pharma Inc position peaked at $14.3M in Q1 2022.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on Prosight Management's 13F filing for Q1 2023, filed 12 May 2023.